Exenatide: incretin therapy for patients with Type 2 diabetes mellitus

References

• Fujioka K. Pathophysiology of Type 2 diabetes and the role of incretin hormones and β-cell dysfunction. JAAPA (Suppl.), 3–8 (2007).
   PubMedGoogle Scholar
• Global guideline for Type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet. Med.23(6), 579–593 (2006).
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycaemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia49(8), 1711–1721 (2006).
   PubMed Web of Science ®Google Scholar
• Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in Type 2 diabetes. N. Engl. J. Med.358(6), 580–591 (2008).
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with Type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA281(21), 2005–2012 (1999).
   PubMed Web of Science ®Google Scholar
• Gagliardi L, Wittert G. Management of obesity in patients with Type 2 diabetes mellitus. Curr. Diabetes Rev.3(2), 95–101 (2007).
   PubMedGoogle Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet352(9131), 837–853 (1998).
   Google Scholar
• Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Pract.28(2), 103–117 (1995).
   PubMed Web of Science ®Google Scholar
• Fox KM, Gerber Pharmd RA, Bolinder B, Chen J, Kumar S. Prevalence of inadequate glycemic control among patients with Type 2 diabetes in the United Kingdom general practice research database: a series of retrospective analyses of data from 1998 through 2002. Clin. Ther.28(3), 3188–395 (2006).
   Google Scholar
• Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with Type 2 diabetes: a preliminary report. Diabetes Care27(1), 17–20 (2004).
   PubMed Web of Science ®Google Scholar
• Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia45(7), S23–S28 (2002).
   PubMed Web of Science ®Google Scholar
• Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care29(9), 2137–2139 (2006).
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med.7, 355(23), 2427–2443 (2006).
   Google Scholar
• Del PS, Bianchi C, Marchetti P. β-cell function and anti-diabetic pharmacotherapy. Diabetes Metab. Res. Rev.23(7), 518–527 (2007).
   PubMed Web of Science ®Google Scholar
• Black C, Donnelly P, McIntyre L, Royle PL, Shepherd JP, Thomas S. Meglitinide analogues for Type 2 diabetes mellitus. Cochrane Database Syst. Rev.2, CD004654 (2007).
   Google Scholar
• Ahren B. DPP-4 inhibitors. Best Pract. Res. Clin. Endocrinol. Metab.21(4), 517–533 (2007).
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology132(6), 2131–2157 (2007).
   PubMed Web of Science ®Google Scholar
• Moore B. On the treatment of diabetus mellitus by acid extract of duodenal mucous membrane. Biochem. J.1(1), 28–38 (1906).
   PubMedGoogle Scholar
• Elrick H, Stimmler L, Hlad CJ Jr, Rai Y. Plasma insulin response to oral and intravenous glucose administration. J. Clin. Endocrinol. Metab.24, 1076–1082 (1964)
   PubMed Web of Science ®Google Scholar
• Ahren B. Gut peptides and Type 2 diabetes mellitus treatment. Curr. Diab. Rep.3(5), 365–372 (2003).
   PubMedGoogle Scholar
• Green BD, Flatt PR. Incretin hormone mimetics and analogues in diabetes therapeutics. Best Pract. Res. Clin. Endocrinol. Metab.21(4), 497–516 (2007).
   PubMed Web of Science ®Google Scholar
• Nauck MA, Homberger E, Siegel EG et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J. Clin. Endocrinol. Metab.63(2), 492–498 (1986).
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol. Endocrinol.17(2), 161–171 (2003).
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Glucagon-like peptide-1 and the islet β-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology144(12), 5145–5148 (2003).
   PubMed Web of Science ®Google Scholar
• Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab.80(3), 952–957 (1995).
   PubMed Web of Science ®Google Scholar
• Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J. Biol. Chem.267(11), 7402–7405 (1992).
   PubMed Web of Science ®Google Scholar
• Barnett A. Exenatide. Expert. Opin Pharmacother.8(15), 2593–2608 (2007).
   PubMed Web of Science ®Google Scholar
• Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with Type 2 diabetes. Diabetes Care27(11), 2628–2635 (2004).
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with Type 2 diabetes. Diabetes Care28(5), 1092–1100 (2005).
   PubMed Web of Science ®Google Scholar
• Fineman MS, Bicsak TA, Shen LZ et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with Type 2 diabetes. Diabetes Care26(8), 2370–2377 (2003).
   PubMed Web of Science ®Google Scholar
• Kolterman OG, Buse JB, Fineman MS et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with Type 2 diabetes. J. Clin. Endocrinol. Metab.88(7), 3082–3089 (2003).
   PubMed Web of Science ®Google Scholar
• Nelson P, Poon T, Guan X, Schnabel C, Wintle M, Fineman M. The incretin mimetic exenatide as a monotherapy in patients with Type 2 diabetes. Diabetes Technol. Ther.9(4), 317–326 (2007).
   PubMed Web of Science ®Google Scholar
• Poon T, Nelson P, Shen L et al. Exenatide improves glycemic control and reduces body weight in subjects with Type 2 diabetes: a dose-ranging study. Diabetes Technol. Ther.7(3), 467–477 (2005).
   PubMedGoogle Scholar
• Barnett AH, Burger J, Johns D et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with Type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin. Ther.29(11), 2333–2348 (2007).
   PubMed Web of Science ®Google Scholar
• Dupre J, Behme MT, McDonald TJ. Exendin-4 normalized postcibal glycemic excursions in Type 1 diabetes. J. Clin. Endocrinol. Metab.89(7), 3469–3473 (2004).
   PubMed Web of Science ®Google Scholar
• Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled Type 2 diabetes: a randomized trial. Ann. Intern. Med.143(8), 559–569 (2005).
   PubMed Web of Science ®Google Scholar
• Kolterman OG, Kim DD, Shen L et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with Type 2 diabetes mellitus. Am. J. Health Syst. Pharm.62(2), 173–181 (2005).
   PubMed Web of Science ®Google Scholar
• Linnebjerg H, Kothare PA, Skrivanek Z et al. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes. Diabet. Med.23(3), 240–245 (2006).
   PubMed Web of Science ®Google Scholar
• Mari A, Nielsen LL, Nanayakkara N, DeFronzo RA, Ferrannini E, Halseth A. Mathematical modeling shows exenatide improved β-cell function in patients with Type 2 diabetes treated with metformin or metformin and a sulfonylurea. Horm. Metab. Res.38(12), 838–844 (2006).
   PubMed Web of Science ®Google Scholar
• Nauck MA, Duran S, Kim D et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with Type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia50(2), 259–267 (2007).
   PubMed Web of Science ®Google Scholar
• Degn KB, Brock B, Juhl CB et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes53(9), 2397–2403 (2004).
   PubMed Web of Science ®Google Scholar
• Fehse F, Trautmann M, Holst JJ et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with Type 2 diabetes. J. Clin. Endocrinol. Metab.90(11), 5991–5997 (2005).
   PubMed Web of Science ®Google Scholar
• Egan JM, Meneilly GS, Elahi D. Effects of 1-mo bolus subcutaneous administration of exendin-4 in Type 2 diabetes. Am. J. Physiol. Endocrinol. Metab.284(6), E1072–E1079 (2003).
   PubMed Web of Science ®Google Scholar
• Taylor K, Kim D, Nielsen LL, Aisporna M, Baron AD, Fineman MS. Day-long subcutaneous infusion of exenatide lowers glycemia in patients with Type 2 diabetes. Horm. Metab. Res.37(10), 627–632 (2005).
   PubMedGoogle Scholar
• Woerle HJ, Albrecht M, Linke R et al. Importance of changes in gastric emptying for postprandial plasma glucose fluxes in healthy humans. Am. J. Physiol. Endocrinol. Metab.294(1), E103–E109 (2008).
   PubMed Web of Science ®Google Scholar
• Woerle HJ, Szoke E, Meyer C et al. Mechanisms for abnormal postprandial glucose metabolism in Type 2 diabetes. Am. J. Physiol. Endocrinol. Metab.290(1), E67–E77 (2006).
   PubMed Web of Science ®Google Scholar
• Woerle HJ, Meyer C, Dostou JM et al. Pathways for glucose disposal after meal ingestion in humans. Am. J. Physiol. Endocrinol. Metab.284(4), E716–E725 (2003).
   Google Scholar
• Horowitz M, O’Donovan D, Jones KL, Feinle C, Rayner CK, Samsom M. Gastric emptying in diabetes: clinical significance and treatment. Diab. Med.19(3), 177–194 (2002).
   PubMed Web of Science ®Google Scholar
• Horowitz M, Edelbroek MAL, Wishart JM, Straathof JW. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia36(9), 857–862 (2003).
   Google Scholar
• Edwards CM, Stanley SA, Davis R et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am. J. Physiol. Endocrinol. Metab.281(1), E155–E161 (2001).
   PubMed Web of Science ®Google Scholar
• Clements JA, Heading RC, Nimmo WS, Prescott LF. Kinetics of acetaminophen absorption and gastric emptying in man. Clin. Pharmacol. Ther.24(4), 420–431 (1978).
   PubMed Web of Science ®Google Scholar
• Baggio L, Adatia F, Bock T, Brubaker PL, Drucker DJ. Sustained expression of exendin-4 does not perturb glucose homeostasis, β-cell mass, or food intake in metallothionein-preproexendin transgenic mice. J. Biol. Chem.275(44), 34471–34477 (2000).
   PubMedGoogle Scholar
• Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in Type 2 diabetic patients. Diabetes Care22(7), 1137–1143 (1999).
   PubMed Web of Science ®Google Scholar
• Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest.101(3), 515–520 (1998).
   PubMed Web of Science ®Google Scholar
• Gutzwiller JP, Goke B, Drewe J et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut44(1), 81–86 (1999).
   PubMed Web of Science ®Google Scholar
• Copley K, McCowen K, Hiles R, Nielsen LL, Young A, Parkes DG. Investigation of exenatide elimination and its in vivo and in vitro degradation. Curr. Drug Metab.7(4), 367–374 (2006).
   PubMed Web of Science ®Google Scholar
• Simonsen L, Holst JJ, Deacon CF. Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs. Diabetologia49(4), 706–712 (2006).
   PubMed Web of Science ®Google Scholar
• Calara F, Taylor K, Han J et al. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin. Ther.27(2), 210–215 (2005).
   PubMed Web of Science ®Google Scholar
• Linnebjerg H, Kothare PA, Park S et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br. J. Clin. Pharmacol.64(3), 317–327 (2007).
   PubMed Web of Science ®Google Scholar
• Ratner RE, Maggs D, Nielsen LL et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with Type 2 diabetes mellitus. Diabetes Obes. Metab.8(4), 419–428 (2006).
   PubMed Web of Science ®Google Scholar
• Riddle MC, Henry RR, Poon TH et al. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with Type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab. Res. Rev.22(6), 483–491 (2006).
   PubMed Web of Science ®Google Scholar
• Blonde L, Klein EJ, Han J et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with Type 2 diabetes. Diabetes Obes. Metab.8(4), 436–447 (2006).
   PubMed Web of Science ®Google Scholar
• Buse JB, Klonoff DC, Nielsen LL et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with Type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin. Ther.29(1), 139–153 (2007).
   PubMed Web of Science ®Google Scholar
• Klonoff DC, Buse JB, Nielsen LL et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with Type 2 diabetes treated for at least 3 years. Curr. Med. Res. Opin.24(1), 275–286 (2008).
   PubMed Web of Science ®Google Scholar
• Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with Type 2 diabetes. Diabetes Metab. Res. Rev.20(5), 411–417 (2004)
   PubMed Web of Science ®Google Scholar
• Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with Type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care28(5), 1083–1091 (2005).
   PubMed Web of Science ®Google Scholar
• Zinman B, Hoogwerf BJ, Duran GS et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled Type 2 diabetes: a randomized trial. Ann. Intern. Med.146(7), 477–485 (2007).
   PubMed Web of Science ®Google Scholar
• Malozowski S. Exenatide in combination therapy: small study, big market, and many unanswered questions. Ann. Intern. Med.146(7), 527–528 (2007).
   PubMedGoogle Scholar
• Home PD. Comment on: Nauck MA, Duran S, Kim D et al. (2007). A comparison of twice-daily exenatide and biphasic insulin aspart in patients with Type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia50, 259–267 (2007).
   PubMedGoogle Scholar
• Brodows RG, Qu Y, Johns D, Kim D, Holcombe JH. Quantifying the effect of exenatide and insulin glargine on postprandial glucose excursions in patients with Type 2 diabetes. Curr. Med. Res. Opin.24(5), 1395–1397 (2008).
   PubMed Web of Science ®Google Scholar
• Brodows R, Milton D, Mao J, Wintle M, Trautmann M. Predictors of achieving glycaemic targets in patients with Type 2 diabetes treated with exenatide or insulin. Diabetologia50(Suppl.1), S352–S353 (2007).
   Google Scholar
• Davis SN, Johns D, Maggs D, Xu H, Northrup JH, Brodows RG. Exploring the substitution of exenatide for insulin in patients with Type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care30(11), 2767–2772 (2007).
   PubMed Web of Science ®Google Scholar
• Denker PS, Dimarco PE. Exenatide (exendin-4)-induced pancreatitis: a case report. Diabetes Care29(2), 471 (2006).
   PubMed Web of Science ®Google Scholar
• Kothare PA, Linnebjerg H, Skrivanek Z et al. Exenatide effects on statin pharmacokinetics and lipid response. Int. J. Clin. Pharmacol. Ther.45(2), 114–120 (2007).
   PubMed Web of Science ®Google Scholar
• Kothare PA, Soon DK, Linnebjerg H et al. Effect of exenatide on the steady-state pharmacokinetics of digoxin. J. Clin. Pharmacol.45(9), 1032–1037 (2005).
   PubMed Web of Science ®Google Scholar
• Blase E, Taylor K, Gao HY, Wintle M, Fineman M. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. J. Clin. Pharmacol.45(5), 570–577 (2005).
   PubMed Web of Science ®Google Scholar
• Soon D, Kothare PA, Linnebjerg H et al. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. J. Clin. Pharmacol.46(10), 1179–1187 (2006).
   PubMed Web of Science ®Google Scholar
• Gedulin BR, Nikoulina SE, Smith PA et al. Exenatide (exendin-4) improves insulin sensitivity and β-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology146(4), 2069–2076 (2005).
   PubMed Web of Science ®Google Scholar
• Stoffers DA, Desai BM, DeLeon DD, Simmons RA. Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat. Diabetes52(3), 734–740 (2003).
   PubMed Web of Science ®Google Scholar
• Tourrel C, Bailbe D, Meile MJ, Kergoat M, Portha B. Glucagon-like peptide-1 and exendin-4 stimulate β-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes50(7), 1562–1570 (2001).
   PubMed Web of Science ®Google Scholar
• Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B. Persistent improvement of Type 2 diabetes in the Goto-Kakizaki rat model by expansion of the β-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes51(5), 1443–1452 (2002).
   PubMed Web of Science ®Google Scholar
• Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes48(12), 2270–2276 (1999).
   PubMed Web of Science ®Google Scholar
• Gallwitz B. Exenatide in Type 2 diabetes: treatment effects in clinical studies and animal study data. Int. J. Clin. Pract.60(12), 1654–1661 (2006).
   PubMed Web of Science ®Google Scholar
• Ghofaili KA, Fung M, Ao Z et al. Effect of exenatide on β-cell function after islet transplantation in type 1 diabetes. Transplantation83(1), 24–28 (2007).
   PubMed Web of Science ®Google Scholar
• Kim D, MacConell L, Zhuang D et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with Type 2 diabetes. Diabetes Care30(6), 1487–1493 (2007).
   PubMed Web of Science ®Google Scholar
• Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P. Exenatide therapy in obese patients with Type 2 diabetes mellitus treated with insulin. Endocr. Pract.13(5), 444–450 (2007).
   PubMedGoogle Scholar